Measurement of Glycated Hemoglobin Does Not Aid in Predicting CVD Risk
By LabMedica International staff writers Posted on 07 Apr 2014 |
Image: Model of a molecule of glycated hemoglobin (HbA1c) (Photo courtesy of Molecular Models, Inc.).
Determination of levels of glycated hemoglobin (HbA1c) does not aid in identifying individuals at risk of developing cardiovascular disease (CVD) according to a recent study.
HbA1c is a derivative of hemoglobin that is formed nonenzymically by reaction at the N terminus of the protein molecule with glucose. In the normal adult human such derivatives constitute a few percent of the total erythrocyte hemoglobin, the most abundant being hemoglobin A1c, which increases several fold in concentration in diabetes mellitus, and is assayed to monitor control of diabetes. Once a hemoglobin molecule is glycated, it remains that way. A buildup of glycated hemoglobin within the red cell, therefore, reflects the average level of glucose to which the cell has been exposed during its life-cycle. Measuring glycated hemoglobin assesses the effectiveness of therapy by monitoring long-term serum glucose regulation. The HbA1c level is proportional to average blood glucose concentration over the previous four weeks to three months.
The recent HbA1c study was conducted in association with The Emerging Risk Factors Collaboration (ERFC), which has established a central database on over two million participants from more than 125 prospective population-based studies, in which subsets have information on lipid and inflammatory markers, other established risk factors and characteristics, as well as major cardiovascular morbidity and cause-specific mortality. Information on repeat measurements on relevant characteristics has been collected for over 300,000 participants to enable estimation of and adjustment for within-person variability.
In the current study, investigators at the University of Cambridge (United Kingdom) analyzed data from 73 studies involving 294,998 participants to discover whether adding information on HbA1c levels to information about conventional cardiovascular risk factors was associated with improvements in the prediction of CVD risk.
They determined that adding information on levels of HbA1c to conventional CVD risk factors was associated with only slight improvement in risk discrimination. In addition, they found that adding information on HbA1c did not improve the accuracy of probability predictors for patients with and without CVD. "Contrary to recommendations in some guidelines, the current analysis of individual-participant data in almost 300,000 people without known diabetes and CVD at baseline indicates that measurement of HbA1c is not associated with clinically meaningful improvement in assessment of CVD risk," said the authors.
The study was published in the March 2014 issue of Journal of the American Medical Association.
Related Links:
University of Cambridge
HbA1c is a derivative of hemoglobin that is formed nonenzymically by reaction at the N terminus of the protein molecule with glucose. In the normal adult human such derivatives constitute a few percent of the total erythrocyte hemoglobin, the most abundant being hemoglobin A1c, which increases several fold in concentration in diabetes mellitus, and is assayed to monitor control of diabetes. Once a hemoglobin molecule is glycated, it remains that way. A buildup of glycated hemoglobin within the red cell, therefore, reflects the average level of glucose to which the cell has been exposed during its life-cycle. Measuring glycated hemoglobin assesses the effectiveness of therapy by monitoring long-term serum glucose regulation. The HbA1c level is proportional to average blood glucose concentration over the previous four weeks to three months.
The recent HbA1c study was conducted in association with The Emerging Risk Factors Collaboration (ERFC), which has established a central database on over two million participants from more than 125 prospective population-based studies, in which subsets have information on lipid and inflammatory markers, other established risk factors and characteristics, as well as major cardiovascular morbidity and cause-specific mortality. Information on repeat measurements on relevant characteristics has been collected for over 300,000 participants to enable estimation of and adjustment for within-person variability.
In the current study, investigators at the University of Cambridge (United Kingdom) analyzed data from 73 studies involving 294,998 participants to discover whether adding information on HbA1c levels to information about conventional cardiovascular risk factors was associated with improvements in the prediction of CVD risk.
They determined that adding information on levels of HbA1c to conventional CVD risk factors was associated with only slight improvement in risk discrimination. In addition, they found that adding information on HbA1c did not improve the accuracy of probability predictors for patients with and without CVD. "Contrary to recommendations in some guidelines, the current analysis of individual-participant data in almost 300,000 people without known diabetes and CVD at baseline indicates that measurement of HbA1c is not associated with clinically meaningful improvement in assessment of CVD risk," said the authors.
The study was published in the March 2014 issue of Journal of the American Medical Association.
Related Links:
University of Cambridge
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines